Literature DB >> 9686831

Kawasaki disease followed by haemophagocytic syndrome.

K Kaneko, K Takahashi, S Fujiwara, T Maruyama, K Obinata.   

Abstract

Entities:  

Mesh：

Year:  1998        PMID： 9686831     DOI： 10.1007/s004310050893

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  6 in total

1.  Langerhans histiocytosis, haemophagocytic syndrome and Epstein-Barr virus infection.

Authors:  Lucien Corbeel
Journal:  Eur J Pediatr       Date:  2004-07-09       Impact factor: 3.183

2.  Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease.

Authors:  Hae-Ryong Kang; Yong-Hoon Kwon; Eun-Sun Yoo; Kyung-Ha Ryu; Ji Yoon Kim; Heung-Sik Kim; Hwang Min Kim; Young-Ho Lee
Journal:  Blood Res       Date:  2013-12-24

3.  Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases.

Authors:  Cheng-I Lin; Hsin-Hui Yu; Jyh-Hong Lee; Li-Chieh Wang; Yu-Tsan Lin; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Clin Rheumatol       Date:  2012-05-22       Impact factor: 3.650

4.  Macrophage activation syndrome triggered by coeliac disease: a unique case report.

Authors:  J Palman; J May; C Pilkington
Journal:  Pediatr Rheumatol Online J       Date:  2016-12-09       Impact factor: 3.054

5.  Differentiation between incomplete Kawasaki disease and secondary hemophagocytic lymphohistiocytosis following Kawasaki disease using N-terminal pro-brain natriuretic peptide.

Authors:  Jung Eun Choi; Yujin Kwak; Jung Won Huh; Eun-Sun Yoo; Kyung-Ha Ryu; Sejung Sohn; Young Mi Hong
Journal:  Korean J Pediatr       Date:  2018-05-28

Review 6.  Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison.

Authors:  Chetan Sharma; Madhusudan Ganigara; Caroline Galeotti; Joseph Burns; Fernando M Berganza; Denise A Hayes; Davinder Singh-Grewal; Suman Bharath; Sujata Sajjan; Jagadeesh Bayry
Journal:  Nat Rev Rheumatol       Date:  2021-10-29       Impact factor: 20.543
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.